<DOC>
	<DOCNO>NCT02654769</DOCNO>
	<brief_summary>The objective study evaluate safety therapeutic equivalence generic ingenol mebutate gel , 0.05 % Picato gel , 0.05 % establish superiority efficacy two product vehicle gel treatment Actinic Keratosis ( AK ) trunk extremity .</brief_summary>
	<brief_title>A Study Equivalence Generic Ingenol Mebutate Gel 0.05 % Picato Gel 0.05 % Subjects With Actinic Keratosis</brief_title>
	<detailed_description>PicatoÂ® ( ingenol mebutate ) gel first ingenol mebutate product approve FDA 2012 topical treatment AK ( ) face scalp ( 0.015 % formulation ) trunk extremity ( 0.05 % formulation ) . A generic ingenol mebutate gel , 0.05 % developed topical treatment clinically typical , visible , discrete non-hyperkeratotic , non-hypertrophic AK lesion trunk extremity .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Subject male nonpregnant female 18 year age old Subject provide write informed consent . Subject willing able apply test article direct , comply study instruction , commit followup visit duration study . Subject clinical diagnosis AK Baseline least four ( 4 ) , eight ( 8 ) , visible discrete nonhyperkeratotic , nonhypertrophic AK lesion , least 4 mm diameter , within contiguous 25 cm2 treatment area ( `` Treatment Area '' ) trunk extremity . Subject good general health free disease state physical condition might impair evaluation AK lesion , investigator 's opinion , expose subject unacceptable risk study participation . Females must postmenopausal , surgically sterile , use effective method birth control , negative urine pregnancy test ( UPT ) Baseline Visit . Subject pregnant , lactating , plan become pregnant study . Subject currently enrol investigational drug device study . Subject use investigational drug investigational device treatment within 30 day prior Baseline Visit . Subject hyperkeratotic , hypertrophic , large matlike AKs ( e.g. , AK &gt; 1 cm2 size ) within contiguous 25 cm2 Treatment Area . Subject eight ( 8 ) AKs , independent size , within contiguous 25 cm2 Treatment Area . Subject need plan expose artificial tanning device excessive sunlight trial . Subject immunosuppressed ( e.g. , HIV , systemic malignancy , graft host disease , etc . ) Subject experience unsuccessful outcome previous ingenol mebutate therapy ( unsuccessful outcome define reasonable therapeutic trial compliance issue topical drug work ) . Subject history sensitivity ingredient test article ( see Section 9.4.2 ) . Subject use topical cream , lotion , gel kind within select Treatment Area within one ( 1 ) day prior entry study . Subject use topical medication ; corticosteroid , alpha hydroxy acid ( e.g. , glycolic acid , lactic acid etc . &gt; 5 % ) , beta hydroxy acid ( salicylic acid &gt; 2 % ) , urea &gt; 5 % , 5fluorouracil , diclofenac , imiquimod , ingenol mebutate , prescription retinoids ( e.g. , tazarotene , adapalene , tretinoin ) within select Treatment Area ( trunk extremity ) within one ( 1 ) month prior Baseline Visit . Subject cryodestruction , curettage , photodynamic therapy , surgical excision , treatment AK within select Treatment Area ( trunk extremity ) within one ( 1 ) month prior Baseline Visit . Subject use oral corticosteroid therapy , interferon , cytotoxic drug , immunomodulators , immunosuppressive therapy , retinoids within one ( 1 ) month prior Baseline Visit . Subject dermatologic procedure surgery laser resurfacing , Psoralen + ultraviolet A ( PUVA ) therapy , ultraviolet B ( UVB ) therapy , chemical peel , dermabrasion select Treatment area ( trunk extremity ) within six ( 6 ) month prior Baseline Visit . Subject lesion suspicious skin cancer ( skin cancer rule biopsy ) untreated skin cancer within select Treatment Area ( trunk extremity ) . Subject skin pathology condition , investigator 's opinion , could interfere evaluation test article require use interfere topical , systemic , surgical therapy . Subject condition , investigator 's opinion , would make unsafe precluded subject 's ability fully participate research study . Subject unable communicate cooperate investigator due language problem , poor mental development , impaired cerebral function , physical limitation . Subject know noncompliant unlikely comply requirement study protocol ( e.g. , due alcoholism , drug dependency , mental incapacity ) opinion investigator . Subject previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>